Haemonetics Corporation

NYSE:HAE

Medical - Instruments & Supplies

Healthcare
$122.86 +1.15%

+$0.84 today

Market cap
$5.59B
Beta
0.54
P/E (TTM)
34.9
EPS (TTM)
$2.11
52W Low $47.32High $87.32

Volume 0.48M

Average 0.88M

HAE Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Haemonetics CorporationNYSE: HAE

Net Debt · Q1 FY2027 · quarter ended Jun 2026

Net debt rises 2.0% from a year ago

Net debt stood at $950.77M at the end of Q1 FY2027, up 2.0% from a year earlier and down 2.9% from the prior quarter. Over 3 fiscal years it compounded at +26.7% a year.

Context

  • Net debt amounted to 40.2% of total assets at the end of Q1 FY2027, up 2.3 pp from a year earlier.
  • Net debt increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +2.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$950.77M-2.9% QoQ
Last fiscal yearMar 2026
$979.14M+6.7% YoY
Year agoJun 2025
$931.88M+2.0% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.0%——
1 year+6.7%——
3-year CAGR+26.7%——
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2026
979.14M USD
Year-over-year change
+6.7%
4-year CAGR
+17.1%

Net Debt vs competitors

How HAE compares with its peers on the latest reported figures

  • HAE's Jun 2026 net debt of $950.77M is the 6th highest of the 10 companies compared; the peer median is $1.34B.
  • Its year-over-year change of +2.0% is the 6th highest of 10, against a peer median of +3.5%.
  • Net debt amounts to 40.2% of total assets for HAE, versus a peer median of 40.9%.
HAE Competitors Peer median
Net Debt for HAE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BHCBausch Health Companies Inc.Jun 2026$18.95B -5.3%-0.5%76.4%
QDELQuidelOrtho CorporationMar 2026$2.73B +6.5%+1.4%48.6%
XRAYDENTSPLY SIRONA Inc.Mar 2026$2.14B +5.7%+6.3%40.9%
CONConcentra Group Holdings Parent, Inc.Sep 2026$2.04B -2.2%+26.4%67.8%
ITGRInteger Holdings CorporationJul 2026$1.34B +3.5%+12.0%39.2%
HAEHaemonetics CorporationJun 2026$950.77M +2.0%+26.7%40.2%
LMATLeMaitre Vascular, Inc.Mar 2026$162.96M +1.8%—25.9%
BEAMBeam Therapeutics Inc.Jun 2026$27.53M +121.6%—2.0%
WRBYWarby Parker Inc.Jun 2026-$41.7M +28.1%—5.4%
CPRXCatalyst Pharmaceuticals, Inc.Mar 2026-$753.18M -30.4%—65.6%
Peer median (excluding HAE) $1.34B+3.5%+6.3%40.9%

Competitors are the stored peer set for HAE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Cash & Equivalents259.5M284.47M178.8M306.76M245.44M
Short-term Investments00000
Net Receivables159.38M179.14M206.56M202.66M216.86M
Inventory293.03M259.38M317.2M365.14M306.37M
Other Current Assets046.74M66.34M60.41M66.21M
Total Current Assets756.03M769.72M768.9M934.98M834.88M
Property, Plant & Equipment (Net)258.48M310.89M366.63M284.05M305.76M
Goodwill467.29M466.23M565.08M604.27M656.37M
Intangible Assets310.26M275.77M406.12M455.74M447.66M
Long-term Investments00000
Tax Assets4.47M5.24M7.74M7.8M9.52M
Other Non-current Assets63.21M106.98M81.12M164.11M141.74M
Total Non-current Assets1.1B1.17B1.43B1.52B1.56B
Total Assets1.86B1.93B2.2B2.45B2.4B
Account Payables58.37M63.93M73.36M67M51.06M
Short-term Debt214.15M11.78M10.23M303.56M5.02M
Tax Payables13.91M0000
Deferred Revenue26.81M30.21M31.24M43.35M42.31M
Other Current Liabilities87.2M81.42M104.85M104.79M116.03M
Total Current Liabilities442.27M251.82M300.38M578.11M282.6M
Long-term Debt559.44M754.1M797.56M921.23M1.22B
Deferred Tax Liabilities28.73M36.2M62.64M62.58M38.05M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities79.88M74.72M75.04M68.19M59.39M
Total Non-current Liabilities668.04M865.01M935.25M1.05B1.32B
Total Liabilities1.11B1.12B1.24B1.63B1.6B
Common Stock511K504K508K482K453K
Retained Earnings202.39M253.17M360.46M352.17M279.34M
Accumulated OCI(25.95M)(30.38M)(35.63M)(55.08M)(37.61M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity749.42M818M959.96M820.84M796.32M
Total Debt780.79M765.89M807.79M1.22B1.22B
Net Debt521.29M481.42M628.99M918.03M979.14M

Haemonetics Corporation

NYSE:HAE

Intrinsic Alpha fair value

Locked

Current Price

$122.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.